Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer

Published:2013-01 Issue:1 Volume:79 Page:33-39
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Yang Jin-Ji,Chen Hua-Jun,Yan Hong-Hong,Zhang Xu-Chao,Zhou Qing,Su Jian,Wang Zhen,Xu Chong-Rui,Huang Yi-Sheng,Wang Bin-Chao,Yang Xue-Ning,Zhong Wen-Zhao,Nie Qiang,Liao Ri-Qiang,Jiang Ben-Yuan,Dong Song,Wu Yi-Long

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference44 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

3. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung;Han;J Clin Oncol,2012

4. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

5. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lokaltherapie im Stadium IV bei Oligopersistenz oder Progression;Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie;2024-08

2. The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer;Anti-Cancer Drugs;2024-02-23

3. Molecular features and clinical outcomes of EGFR-mutated, MET-amplified non-small-cell lung cancer after resistance to dual-targeted therapy;Therapeutic Advances in Medical Oncology;2024-01

4. Analysis of the Clinical Efficacy of Dendritic Cell-Cytokine Induced Killer Immunotherapy Combined with TKIs in Treatment of Drug-Resistant Non-Small Lung Cancer;2024

5. Clinical Characteristics and Prognostic Factors of Leptomeningeal Metastasis in Nonsmall Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutations;2024